Eur Rev Med Pharmacol Sci 2019; 23 (1 Suppl): 39-43

DOI: 10.26355/eurrev_201903_17347

Bacteriotherapy in children with recurrent upper respiratory tract infections

V. Tarantino, V. Savaia, R. D’Agostino, M. Silvestri, F.M. Passali, S. Di Girolamo, G. Ciprandi

Dipartimento Testa-Collo e Neuroscienze – IRCCS Istituto Giannina Gaslini, Genoa, Italy gio.cip@libero.it


OBJECTIVE: Children with recurrent upper-airway infections (UI) represent a social issue for their economic burden and negative impact on families. Bacteriotherapy is a new therapeutic strategy that could potentially prevent infections. The current study tested the hypothesis that recurrent UI may be prevented by bacteriotherapy.

PATIENTS AND METHODS: This open study was conducted in an outpatient clinic, enrolling 80 children (40 males, mean age 5.26±2.52 years) suffering from recurrent UI. Children were treated with a nasal spray containing Streptococcus salivarius 24SMB and Streptococcus oralis 89a, 2 puffs per nostril twice a day for a week; this course was repeated for 3 months. The evaluated parameters were: number of UI and number of school and work absences; these outcomes were compared with those recorded in the past year.

RESULTS: The mean number of UI significantly diminished: from 5.98 (2.30) in the past year to 2.75 (2.43) after treatment (p<0.0001). The number of school and work absences significantly diminished (from 4.50±2.81 to 2.80±3.42 and from 2.33±2.36 to 1.48±2.16 respectively; p<0.0001 for both).

CONCLUSIONS: This preliminary experiment suggests that bacteriotherapy using Streptococcus salivarius 24SMB and Streptococcus oralis89a nasal spray could prevent recurrent UI in children.

Free PDF Download

To cite this article

V. Tarantino, V. Savaia, R. D’Agostino, M. Silvestri, F.M. Passali, S. Di Girolamo, G. Ciprandi
Bacteriotherapy in children with recurrent upper respiratory tract infections

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 1 Suppl
Pages: 39-43
DOI: 10.26355/eurrev_201903_17347